

# Lexaria Bioscience Corp.

12:26 14 Jan 2020

## Buds & Duds: Lexaria Bioscience shines while Aphria tumbles on slashed revenue outlook

Cannabis stocks were mixed on Tuesday as the Horizons marijuana ETF perked up but others stayed flat.

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was flat at 118 points. Elsewhere, the Horizons Marijuana Life Sciences Index ETF jumped 1.1% to C\$8.95, while the OTCQX Cannabis index rose 0.6% to 463.3 points.

### Buds

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) jumped Tuesday after it revealed that it has sealed an agreement to provide its patented DehydraTECH technology to Cannadips CBD.

California-based Cannadips CBD channels one of the most effective methods of smokeless CBD dosing with its Original Smokeless CBD Cannabis Dip Pouch, and the Original Hemp CBD Dip Pouch.

Shares of the Kelowna-based company rose 9.3% in Canada to C\$0.59 and 3.5% over the counter at US\$0.43.

Tilray Inc (NASDAQ:TLRY) also saw its shares move after announcing an expanded leadership team that includes a new COO and CFO.

Shares of the cannabis cultivator were up 5.6% at US\$18.35.

Curaleaf Holdings Inc (CSE:CURA) (OTCMKTS:CURLF) was also in positive territory, up nearly 3% in Canada at C\$9.30 and 3.5% over the counter at US\$7.14 after it received its preliminary processing license in Utah.

### Duds

Aphria Inc (TSE:APHA) (NYSE:APHA) tumbled Tuesday after it slashed its full year outlook and reported second quarter revenue that missed analyst expectations.

The Leamington, Ontario-based firm reported net revenue of C\$120.6 million, an increase from the same period last year, but a decline from the C\$126.1 million it reported in the prior quarter. Analysts expected Aphria to report C\$130.4 million in revenue.


More concerning to investors was its adjusted forecast for fiscal 2020 of C\$575 million to C\$625 million, down from the C\$650 million to C\$700 million the company previously forecast. The decline in projections is owed to "market dynamics," including slower-than-expected retail openings in Ontario, a temporary ban on vape products in Alberta, and a decline in growth in its German pharmaceutical distribution business, the company said in a statement.

As a result, shares slid 6% in New York to US\$5.12 and 5.2% in Toronto to C\$6.73.

**Price:** 0.59

**Market Cap:** \$47.63 m

### 1 Year Share Price Graph



February 2019 August 2019 February 2020

### Share Information

**Code:** LXX

**Listing:** CSE

<b>52 week</b>	<b>High</b>	<b>Low</b>
	1.9	0.4

**Sector:** Cannabis

**Website:** [www.lexariabioscience.com](http://www.lexariabioscience.com)

### Company Synopsis:

Lexaria Bioscience Corp has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. Many vitamins, drugs, supplements and other beneficial molecules are lipophilic (i. e.

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Contact Angela at [angela@proactiveinvestors.com](mailto:angela@proactiveinvestors.com)

Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).